A method for constructing an acute gouty arthritis mouse model and its application
By improving the treatment method and injection technology of sodium urate crystals, a more stable and efficient mouse model of acute gouty arthritis was constructed, solving the problems of purity and operation difficulty of the existing models, and providing a more suitable animal Experimental platform.
Patent Information
- Application Number
- CN202311663115.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-06
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-12-06
AI Technical Summary
During the construction process of the existing gout arthritis model, the purity of urate suspension decreases, affecting the model stability and modeling effect, making it difficult to effectively simulate the pathological process of acute gout arthritis, and the operation is complicated and difficult to apply to drug development. .
Grind the sodium urate crystal into powder, combine it with ultrasonic treatment and resuspend it, and inject the sodium urate crystal suspension into the ankle joint of the mouse using a 0.25mm insulin syringe to adjust the injection site and anesthesia method to improve the injection accuracy and stability.
A more efficient and stable construction of a mouse model for acute gout arthritis has been achieved, which reduces the difficulty of operation, improves the authenticity and application value of the model, and provides a reliable animal experimental basis for the research and development of anti-gout drugs.
Smart Images

Figure CN117653638B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to a method for constructing an acute gouty arthritis mouse model and application thereof. Background Art
[0002] In recent years, relevant studies abroad have shown that about 3.9% of the world's population suffers from gouty arthritis, and the number is getting younger and increasing year by year. Modern medicine believes that acute gouty arthritis (AGA) is caused by the precipitation of uric acid in the form of urate in the joint cavity when the body reaches an oversaturated state, which stimulates the synovium, cartilage and other tissues, causing edema, inflammatory cells infiltrating the surrounding tissues, and causing skin redness, fever and joint pain. In the acute stage, the joints are red, swollen, painful, and dysfunctional, accompanied by increased uric acid. If the acute stage is not well controlled, it will turn into a chronic disease, with repeated attacks, and the disease will linger in the later stage, seriously affecting the patient's quality of life. At the same time, excessive accumulation of urate may form tophi in the joints, or even gouty nephropathy, which will bring heavy physical and economic burdens to patients. It is generally believed that urate (Monosodium urate, MSU) is the main factor inducing AGA and plays a vital role in the development of the disease. Therefore, studying the occurrence and development of AGA and its treatment plan is particularly critical for its prevention and treatment.
[0003] Animal models play an important role in this study and are an important tool for studying the pathogenic mechanism of AGA and drug development. A stable AGA model is of profound significance for studying its occurrence, development and treatment. Currently, most gouty arthritis models are chronic gouty arthritis models induced by hyperuricemia. The model takes a long time to be modeled and is not suitable for the study of AGA diseases. In existing AGA model studies, MSU suspensions are mostly prepared by direct grinding and resuspension, chemical dissolution or physical filtration. Such treatment methods will greatly reduce or lose the purity of MSU and affect the final modeling effect. The present invention improves the shortcomings of existing modeling methods, screens out a modeling method that is closer to human AGA and is stable and efficient, and provides a stable and reliable animal model basis for the development of anti-gout drugs.
[0004] In view of this, the present invention is proposed. Summary of the invention
[0005] The purpose of the present invention is to provide a method for constructing an acute gouty arthritis mouse model and its application to solve the problems existing in the above-mentioned prior art. The present invention provides an improved method for constructing an AGA mouse model. The construction method has simple steps, reduces the difficulty of operation and improves the stability of the animal model. The method can be applied to AGA animal experimental research, and provides an effective means for further studying the occurrence, development and treatment of AGA in the future.
[0006] To achieve the above object, the present invention provides the following solutions:
[0007] The present invention provides a method for constructing an acute gouty arthritis mouse model, comprising the following steps:
[0008] Beat the sodium urate crystals, grind them into powder, resuspend them, and perform ultrasonic treatment to obtain a sodium urate crystal suspension;
[0009] A needle was inserted into the ankle joint of the mouse, and the sodium urate crystal suspension was injected.
[0010] Furthermore, the sodium urate crystals are repeatedly beaten and squeezed and ground into powder, a sodium chloride solution is added to the powder to resuspend it, and the resuspended liquid is ultrasonically treated to harvest the sodium urate crystal suspension.
[0011] Furthermore, the conditions of the ultrasonic treatment are: temperature of 45° C., ultrasonic power of 480 W, and ultrasonic time of 30 min; during the ultrasonic treatment, the resuspension is shaken and inverted once every 5 min.
[0012] Furthermore, before puncturing the ankle joint of the mouse, the mouse was anesthetized by intraperitoneal injection of 2.5% V / V tribromoethanol.
[0013] Furthermore, after the mouse was anesthetized, the ankle joint of the mouse was placed at 90°, and a needle was inserted at an angle of 35° between the right ankle tendon and the base of the lateral malleolus, and sodium urate crystal suspension was injected.
[0014] Furthermore, the injection instrument is a syringe with a pore diameter of 0.25 mm.
[0015] Furthermore, the injection volume of the sodium urate crystal suspension is 75 μL.
[0016] Furthermore, the mice are 6-8 weeks old.
[0017] The present invention also provides an application of the acute gouty arthritis mouse model obtained by the above-mentioned construction method in screening therapeutic drugs for acute gouty arthritis.
[0018] The present invention discloses the following technical effects:
[0019] (1) The present invention has made significant improvements to the injection method, that is, adjustments have been made based on the existing technology, including the mouse joint opening angle and the needle insertion angle. The present invention found that when the mouse ankle joint opening angle is set to 90°, the ankle joint cavity can be exposed to the maximum extent, thereby increasing the injection volume, improving the modeling rate and modeling effect. In addition, inserting the needle at a 35° angle between the right ankle tendon and the base of the lateral malleolus can make the injection smoother. This method is easy to operate and can effectively reduce the difficulty of operation.
[0020] (2) The present invention focuses on improving the preparation method of MSU crystals, and adopts a method of repeated hammering and grinding for pretreatment. After consulting a large amount of information, it was found that the processing methods of MSU crystals are roughly divided into three types: direct grinding, resuspension by filtering through a filter membrane or chemical dissolution and reprecipitation, so as to achieve the purpose of being suitable for the aperture size of the syringe. The present invention has tried these two processing methods in the research, both of which have a large loss or loss of MSU crystal components, resulting in unsatisfactory modeling effects or large differences in overall data, indicating that the concentration of MSU crystal suspension after treatment by this method is uneven. The present method has been improved by repeatedly grinding and hammering the crystals for processing, and at the same time combining ultrasound for 30 minutes for physical dissolution, during which multiple flippings are performed to achieve the purpose of more sufficient crushing. The MSU crystals prepared by the present invention can achieve better modeling effects through smaller aperture syringes.
[0021] (3) The present invention improves the experimental syringe and adopts a 0.25 mm insulin syringe, which is the smallest syringe aperture currently available in the literature and can effectively prevent the MSU suspension from overflowing. At the same time, it can effectively reduce the mechanical damage caused by the excessively large aperture, which is conducive to more realistically reflecting the effect of MSU crystal deposition on the onset of the AGA model.
[0022] (4) The anesthesia method used in the present invention is improved to a more convenient and safe method, that is, 2.5% V / V tribromoethanol is used for intraperitoneal anesthesia. This anesthesia method has a more stable degree of anesthesia during the operation, and does not require continuous anesthesia. This anesthesia method is more convenient for surgical operation and adjustment. In addition, long-term respiratory anesthesia may cause death. In comparison, this anesthesia method is safer.
[0023] (5) The injection volume used in the present invention is 75 μL, which is the largest injection volume of MSU suspension in the currently available data. By adjusting the needle insertion method to increase the MSU injection volume without leakage, the effect of a large amount of MSU deposition on the AGA model can be truly and effectively replicated, providing a stable and efficient AGA model.
[0024] In summary, the present invention provides an improved method for constructing an AGA mouse model, which can be applied to animal experimental research on AGA, and provides an effective means for further studying the occurrence, development and treatment of AGA in the future. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0026] Figure 1 This is a schematic diagram of the construction process of the acute gouty arthritis model;
[0027] Figure 2 Schematic diagram of the preparation process of MSU crystal, where A is the state of the crystal before grinding, B is the grinding process, C is the state of the MSU crystal after grinding, and D is the ultrasonic crushing process;
[0028] Figure 3 This is a comparison diagram of three syringes with different apertures, where A is a schematic diagram of the syringe, and B is a schematic diagram of the syringe aperture, which are 0.45mm, 0.33mm, and 0.25mm from left to right;
[0029] Figure 4 Schematic diagrams of injection effects with different aperture syringes, where A is a schematic diagram of injection with a 0.45 mm aperture syringe, B is a schematic diagram of leakage during injection with a 0.45 mm aperture syringe, C is a schematic diagram of injection with a 0.33 mm aperture syringe, and D is a schematic diagram of injection with a 0.25 mm aperture syringe;
[0030] Figure 5 Schematic diagrams of ankle joint injections of mice injected at different injection sites, where A is a schematic diagram of vertical ankle joint injection, B is a schematic diagram of forward ankle joint injection, C is a diagram of the effect of forward ankle joint injection, and D is a schematic diagram of 35° ankle joint injection;
[0031] Figure 6 Schematic diagram of modeling ankle swelling in mice for different injection sites, where A is the ankle joint vertical injection group, B is the ankle joint forward injection group, and C is the ankle joint 35° injection group;
[0032] Figure 7 Frontal schematic diagram of modeling ankle swelling in mice for different injection sites, where A is the ankle joint vertical injection group, B is the ankle joint forward injection group, and C is the ankle joint 35° injection group;
[0033] Figure 8 The diagram shows the changes in swelling of the right ankle joint of mice injected with different doses; Note: Compared with the control group: **P < 0.01; ***P < 0.001; Compared with the 75μL group: # P < 0.05;
[0034] Fig. 9 The graph shows the changes of uric acid levels in mice injected with different doses; Note: *P<0.05; **P<0.01; **P<0.001;
[0035] Fig.10The graph shows the changes in mechanical pain threshold of mice with different injection doses; Note: Compared with the 75μL group: *P<0.05; **P<0.01; **P<0.001;
[0036] Fig.11 HE staining to detect the pathological changes of ankle joint tissues 3 days after modeling with different injection doses (×200), where A is the control group, B is the 25μL injection group, C is the 50μL injection group, and D is the 75μL injection group;
[0037] Fig.12 This is a comparison of different mouse anesthesia methods, where A and B are schematic diagrams of the mouse inhalation anesthesia device and the anesthesia process; C is a schematic diagram of a mouse anesthetized by intraperitoneal injection of 2.5% tribromoethanol. DETAILED DESCRIPTION
[0038] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0039] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0040] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0041] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0042] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0043] The present invention provides a method for constructing a mouse model of acute gouty arthritis. The schematic diagram of the construction process of this acute gouty arthritis model is as shown in Figure 1 and includes the following steps:
[0044] (1) Select C57BL / 6j mice, male, 6 weeks old, with a body weight of 18 ± 2 g;
[0045] (2) After repeatedly pounding and grinding MSU crystals, add them to 0.9% sodium chloride solution, and prepare a 5% MSU suspension for standby after ultrasonic treatment;
[0046] (3) After the animals are anesthetized, place the mice in a prone position and disinfect the ankle joints;
[0047] (4) Insert a needle into the right ankle joint of the mouse and inject the MSU suspension.
[0048] The present invention has made certain improvements on the basis of the existing technology, including: 1. The MSU crystals are repeatedly pounded and extruded and ground into powder. 2. After the MSU crystals are resuspended with 0.9% sodium chloride, they are ultrasonically treated at a water temperature of 45 °C for 30 min for physical dissolution of the MSU crystals, and are turned over and shaken every 5 min during the ultrasonic treatment to fully crush the MSU crystals. 3. The anesthesia method is improved to a more convenient and more conducive method for operation, that is, 2.5% tribromoethanol is used for intraperitoneal anesthesia. 4. The syringe used in this model is a 0.25 mm insulin syringe with the smallest aperture in the currently seen technology. 5. The injection site is when the mouse ankle joint is placed at 90°, and a needle is inserted and injected at a 35° angle between the tendon of the right ankle joint of the mouse and the base of the outer ankle. 6. The injection volume of the mouse ankle joint is greater than 75 μL of the MSU suspension in the currently seen technology. 7. After the injection is completed, wait for 3 s without leakage and then withdraw the needle by rotating it. This method has the advantages of more convenient and safe operation in the anesthesia method compared with the existing model technology, small injection trauma, high grinding degree and less loss of MSU crystals, large injection volume for model making, not easy to leak liquid, and stable model. The specific research is as follows:
[0049] Example 1
[0050] 1 Materials and methods
[0051] 1.1 Sodium urate crystals
[0052] The sodium urate crystals are sodium urate salts, purchased from Merck KGaA, Germany, and stored at room temperature.
[0053] 1.2 Experimental animals
[0054] The experimental animals are C57BL / 6j mice, male, 6 weeks old, with a body weight of 18 ± 2 g, purchased from Guangdong Pharmaron Biotechnology Co., Ltd., and the experimental animal production license number: SCXK(Yue)2020-0054.
[0055] 1.3 Construction of acute gouty arthritis mouse model
[0056] The method comprises the following steps: (1) preparing experimental animals; (2) preparing sodium urate (MSU) crystal suspension; (3) placing the mouse in a prone position after anesthesia and disinfecting the ankle joint; and (4) puncturing the right ankle joint of the mouse and injecting the MSU suspension.
[0057] This study evaluated the optimal AGA model conditions by comparing different MSU crystal preparation methods, different diameter syringes, different injection sites, different injection doses, different animal ages, and different anesthesia methods.
[0058] (1) Comparison of different MSU crystal preparation methods
[0059] Comparison of three different MSU crystal preparation methods, including:
[0060] Method 1: Referring to the traditional AGA model making method, the MSU crystals were ground and resuspended in a sterile 0.9% sodium chloride solution to prepare an MSU crystal suspension (50 mg / mL) for use.
[0061] Method 2: Grind the MSU crystals, prepare an MSU crystal suspension (50 mg / mL) with a sterile 0.9% sodium chloride solution, and filter through a 40 μm cell filter for later use.
[0062] Method 3: Beat the MSU crystals repeatedly, squeeze and grind them into powder. Add 0.9% sodium chloride to resuspend them into a 5% MSU suspension, and dissolve the crystals physically by ultrasonication (480W) at 45°C for 30 minutes. Shake them every 5 minutes. After the ultrasonication, oscillate them on a vortex oscillator for 1 minute for later use. Figure 2 ).
[0063] Forty-eight 6-week-old male C57BL / 6j mice were randomly divided into 4 groups (Group A-Group D), with 12 mice in each group. Groups A, B and C were infection groups, and Group D was the control group. The mice were injected with MSU suspensions prepared by three methods using syringes with different calibers. Group A was divided into three groups, and the MSU suspension prepared by method 1 was injected with 1mL syringes with apertures of 0.45mm, 0.33mm, and 0.25mm, respectively; Group B was divided into three groups, and the MSU suspension prepared by method 2 was injected with 1mL syringes with apertures of 0.45mm, 0.33mm, and 0.25mm, respectively; Group C was divided into three groups, and the MSU suspension prepared by method 3 was injected with 1mL syringes with apertures of 0.45mm, 0.33mm, and 0.25mm, respectively; Group D was the control group, and 0.9% sodium chloride solution was injected with 1mL syringes with apertures of 0.45mm, 0.33mm, and 0.25mm, respectively, as in Group C. Each mouse was modeled in the same way, that is, the ankle joint was placed at 90°, and the needle was injected at an angle of 35° between the right ankle tendon and the base of the lateral malleolus of the mouse. The MSU suspension was slowly injected after the needle felt empty, and the needle was rotated out after the injection was completed. The injection effects of MSU suspensions prepared by three different preparation methods were compared.
[0064] (2) Comparison of syringes with different apertures
[0065] Forty-eight 6-week-old male C57BL / 6j mice were randomly divided into 4 groups (Group A-Group D), with 12 mice in each group. Groups A, B and C were infection groups, and Group D was the control group. They were injected with syringes of different calibers. Group A used a 1mL syringe with a 0.45mm caliber; Group B used a 1mL insulin syringe with a 0.33mm caliber; Group C used a 1mL insulin syringe with a 0.25mm caliber; Group D was the control group, and the same 0.25mm caliber 1mL insulin syringe was used as the control group. Each mouse was modeled in the same way, that is, the ankle joint was placed at 90°, and 75μL MSU suspension (prepared in method three) was injected from the 35° angle between the right ankle tendon and the base of the lateral malleolus of the mouse. The MSU suspension was slowly injected after the needle felt empty, and the needle was rotated out after the injection was completed. The control group was injected with only 0.9% sodium chloride solution under the same operation.
[0066] (3) Comparison of different injection sites
[0067] Forty-eight 6-week-old male C57BL / 6j mice were randomly divided into 4 groups, with 12 mice in each group. Among them, 3 groups were infection groups and 1 group was the control group. In the infection group, different injection sites were used for modeling (Group A placed the ankle joint at 90° to fully expose the gap between the ankle joint and the tibia and fibula, and the needle was inserted vertically into the joint cavity. The injection point of Group B was the anterior edge of the lateral ankle joint of the right hind limb, and the bevel of the needle mouth was facing forward and upward to penetrate the ankle joint cavity at a 45° angle with the tibia; Group C placed the mouse ankle joint at 90°, and the needle was inserted at a 35° angle between the right ankle tendon and the base of the lateral malleolus of the mouse), and each mouse was injected with 75μL of MSU suspension (prepared by method 3). Group D was the control group, which was operated in the same way as Group C, except that only 75μL of 0.9% sodium chloride solution was injected. All 4 groups used a 1mL insulin syringe with a pore size of 0.25mm.
[0068] (4) Comparison of different injection doses
[0069] Sixty 6-week-old male C57BL / 6j mice were randomly divided into 5 groups, with 12 mice in each group. Among them, 4 groups were infection groups and 1 group was the control group. The infection groups were divided into groups according to different injection doses, namely 25μL, 50μL, 75μL injection volume and 100μL. The ankle joints of each group of mice were placed at 90°, and the needle was inserted at a 35° angle between the right ankle tendon and the base of the lateral malleolus of the mouse. The control group was operated in the same way as above, and only 75μL of 0.9% sodium chloride solution was injected. All 5 groups were injected with MSU suspension prepared by method 3, and all used 1mL insulin syringes with a pore size of 0.25mm.
[0070] (5) Comparison of animals of different ages
[0071] 60 male C57BL / 6j mice were randomly divided into 5 groups of different animal ages for comparison, of which 4 groups were infection groups and 1 group was a control group. The infection groups were 4 weeks old, 6 weeks old, 8 weeks old, and 10 weeks old, respectively, and the control group was 6-week-old healthy mice. Each mouse was modeled in the same way, that is, the ankle joint was placed at 90°, and 75μL of MSU suspension (prepared in method 3) was injected at a 35° angle between the right ankle tendon and the base of the lateral malleolus of the mouse. After the needle felt empty, the MSU suspension was slowly injected, and the needle was rotated out after the injection was completed. The control group was 6-week-old mice with the same operation as above, and only 75μL of 0.9% sodium chloride solution was injected. All 5 groups used a 1mL insulin syringe with a pore size of 0.25mm.
[0072] (6) Comparison of different anesthesia methods
[0073] Twelve male C57BL / 6j mice were randomly divided into two groups for different anesthesia methods. One group was anesthetized by intraperitoneal injection of 2.5% tribromoethanol, and the other group was anesthetized by isoflurane inhalation anesthesia. The anesthetic effects during the operation were compared.
[0074] 1.4 Identification of acute gouty arthritis mouse model
[0075] The infection status of the AGA model was judged by clinical symptoms, joint swelling, blood routine test, ankle joint HE staining, mechanical pain threshold, etc.
[0076] 1.5 Statistical analysis
[0077] SPSS 20.0 statistical software was used to analyze the data. The data results were expressed as (mean ± SD). The differences between different treatment groups were analyzed by t-test and one-way ANOVA. P < 0.05 was considered statistically significant.
[0078] 2 Results
[0079] 2.1 Comparison of different MSU crystal preparation methods
[0080] In method 1, the residual particles of the prepared MSU crystal suspension were large and only suitable for 1mL syringes with a pore size of 0.45mm; in method 2, the residual particles of the prepared MSU crystal suspension were small and suitable for syringes with pore sizes of 0.45mm and 0.33mm, but not for 0.25mm syringes. The molecular particles in the prepared MSU crystal suspension in method 3 were the smallest and suitable for all three syringes (Table 1).
[0081] Table 1 Comparison of injection effects of 3 different MSU preparation methods
[0082]
[0083]
[0084] 2.2 Comparison of syringes with different bore diameters
[0085] Comparison of different syringe bore sizes Figure 3 The 0.45 mm pore size syringe used in group A is likely to cause greater joint damage during the needle insertion process, affecting the modeling effect. In addition, the larger pore size of the syringe is prone to leakage during the modeling process ( Figure 4 In groups A and B). In groups B and C, 0.33 mm and 0.25 mm syringes were used, respectively, and the needle insertion process was smooth and there was no resistance to injection ( Figure 4 (C, D).
[0086] 2.3 Comparison of different injection sites
[0087] Comparison of different injection sites Figure 5 As shown, group A used a vertical needle insertion method, and the injection process was smooth and without resistance ( Figure 5In group B, the needle was inserted into the joint, but the injection site could not complete the 75 μL injection. The needle insertion site was difficult to grasp, and some mice had bleeding after injection ( Figure 5 In group C, the ankle joint was placed at 90°, and the needle was inserted at a 35° angle between the right ankle tendon and the base of the lateral malleolus. This method is easy to operate, with smooth needle insertion and no resistance to injection ( Figure 5 (middle D).
[0088] Effects on joint swelling Figure 6 , Figure 7 As shown in the figure, it can be seen that the vertical needle insertion method does not cause obvious redness and swelling in the ankle joint of mice ( Figure 6 Middle A, Figure 7 Middle A), while the needle was inserted into the joint and at a 35° angle between the tendon and the base of the lateral malleolus of the right ankle joint of the mouse, obvious joint redness and swelling appeared ( Figure 6 (B, C in 7, B, C in 7).
[0089] 2.4 Comparison of different injection doses
[0090] Comparison of mouse joint swelling under different injection doses Figure 8 As shown in the figure, within 72 hours after modeling, all groups were significantly different from the control group (P < 0.05), and the swelling reached its peak at 12 hours and then began to subside. At 24 hours and 48 hours, there was a difference between the 25μL group and the 75μL group (P < 0.05), and there was a difference between the 50μL group and the 75μL group at 24 hours (P < 0.05).
[0091] Comparison of uric acid levels in mice at different injection doses Fig. 9 As shown, 72 hours after modeling, there was a significant difference between the 75μL group and the control group (P < 0.01), and a very significant difference between the 75μL group and the 25μL group (P < 0.001), while there was also a significant difference between the 50μL group and the 25μL group (P < 0.05).
[0092] Comparison of mechanical pain threshold of mice under different injection doses Fig.10 As shown in the figure, at 12, 24 and 48h after modeling, each group was significantly different from the control group (P<0.01). The 75μL group was significantly different from the 25μL group at each time point (P<0.01), and was significantly different from the 50μL group at 24h (P<0.01).
[0093] HE staining 3 days after modeling showed that the ankle cartilage of the mice in the control group was smooth and intact, and no synovial tissue hyperplasia was observed ( Fig.11Middle A); The results of the 25 μL group showed thickening of the synovium on one side of the ankle joint tissue of the mice, hyperplasia of connective tissue, local lymphocyte infiltration and edema ( Fig.11 In the 50 μL group, the connective tissue was loosely arranged and hyperplastic, with a large amount of connective tissue necrosis, dissolution and edema ( Fig.11 In the 75μL group, the synovium on both sides of the joint tissue was significantly thickened, connective tissue hyperplasia and necrotic dissolution were observed, accompanied by diffuse lymphocyte and granulocyte infiltration and mild edema, and local mild bleeding ( Fig.11 (middle D).
[0094] 2.5 Comparison of animals of different ages
[0095] The incidence of different animal ages is shown in Table 2. When the animal age reaches 6 weeks and above, the incidence of AGA model exceeds 90%. Among them, the 6-week-old and 8-week-old animals are most seriously ill after being infected with AGA model, showing severe lameness, the tested joints cannot touch the ground, and they walk on three legs.
[0096] Table 2 The incidence of AGA model in different animal ages
[0097]
[0098] 2.6 Comparison of different anesthesia methods
[0099] The comparison of different anesthesia methods is shown in the figure ( Fig.12 ), the results show that inhalation anesthesia is limited by the anesthesia instrument and anesthesia tube during the operation, which is not convenient for experimental operation and adjustment of the mouse position during the experiment ( Fig.12 In contrast, the use of 2.5% tribromoethanol for anesthesia does not have the above limitations ( Fig.12 Middle C).
[0100] In summary, the improved method of the AGA mouse model provided by the present invention has the characteristics of more convenient and safe anesthesia, simple model operation, not easy to leak, high modeling rate, and rapid onset, and a stable and reliable AGA mouse model is constructed. AGA is an acute rheumatic disease. Because of a certain stimulus, the synovium produces an inflammatory reaction, MSU crystals appear in the joints and periphery, so that inflammatory cells infiltrate, causing severe pain in the patient's joints, especially in acute attacks, not only the pain symptoms will be further aggravated, but also the tissues around the joints will swell, resulting in joint activity dysfunction, and such patients are prone to complications such as urate nephropathy and uric acid urinary tract stones. If not treated in time, severe patients can cause severe joint damage and renal damage, seriously endangering the patient's physical and mental health and quality of life. At present, the global prevalence of gout is gradually increasing, and now it has reached 4%. Animal models play a vital role in the occurrence, development, molecular mechanism and treatment of AGA. They can simulate the different characteristics of human AGA development. Studying AGA animal models is more conducive to simulating the actual clinical incidence. The current AGA model mostly uses MSU crystals to directly grind and resuspend, and then injects them into the model through a 0.45mm syringe. This modeling method has the disadvantages of insufficient grinding, easy needle blockage and leakage, and greater joint damage, and there is still room for improvement. The present invention has made a series of improvements on this basis, including the use of MSU crystals repeatedly hammered and ground and combined with ultrasonic crushing, using a 0.25mm insulin syringe with a very small aperture, and the injection volume is the largest currently seen 75μL, the anesthesia method is 2.5% tribromoethanol, and the injection site is between the right ankle joint tendon and the base of the lateral malleolus. The needle is inserted at a 35° angle, etc., which provides a set of simple and standard reference schemes for the establishment of AGA animal models in the future.
[0101] The specific improvements in the construction of this animal model are as follows:
[0102] 1. Choice of anesthesia method: We use intraperitoneal injection of 2.5% tribromoethanol as anesthesia. Since the mouse posture must be kept stable during the needle insertion process to avoid damage or puncture of the joint cavity, this model has certain requirements for the degree of anesthesia for each mouse during operation. The existing technology uses gas anesthesia, and the degree of anesthesia is difficult to grasp, which is not suitable for experimental operations. In addition, due to the constraints of the anesthesia pipeline, it is not convenient to adjust the position of the mouse during the modeling process, so there is still room for improvement. 2.5% tribromoethanol is currently a relatively safe method of anesthesia for mouse surgery. It has the advantages of fast onset and awakening, and a deeper degree of anesthesia. In addition, it can get rid of the constraints of the anesthesia pipeline, which is convenient for adjusting the position of the mouse during the needle insertion process, and is more in line with the needs of this experiment. Therefore, the present invention uses 2.5% tribromoethanol as the preferred anesthetic for this experiment.
[0103] 2. Selection of MSU crystal preparation method: The present invention focuses on improving the MSU crystal preparation method, and adopts repeated beating and grinding for pretreatment. After consulting a large amount of information, it is found that the treatment methods of MSU crystals are roughly divided into three types: direct grinding and resuspension; dissolution by membrane filtration or chemical dissolution and reprecipitation, so as to achieve the purpose of being suitable for the aperture size of the syringe. The present invention compares these three treatment methods in the embodiments, among which membrane filtration and chemical dissolution and reprecipitation both cause large loss or loss of MSU crystal components, resulting in unsatisfactory modeling effect. The direct grinding and dissolution method has uneven particle distribution, which can easily lead to pinhole clogging, and is therefore not suitable for small-aperture syringes. The present invention has improved the above method by performing crystal pretreatment through repeated grinding and beating, and this step is the key to this method. After multiple grinding and beating, the crystals on the mortar wall are scraped off and then repeatedly ground and beaten. This process is repeated nearly 5 times until it is completely powdery (visible to the naked eye). Figure 2 C). Due to the powder sticking to the wall, the MSU crystals will be lost in this process, so the MSU crystals need to be re-weighed, re-suspended in 0.9% sodium chloride, and physically dissolved by ultrasound for 30 minutes, and turned over several times during the process to achieve the purpose of full crushing. The MSU suspension after the above treatment process has been proven to have many advantages in the embodiments of the present invention.
[0104] 3. Selection of syringes with different apertures: Due to the small volume of the mouse ankle joint cavity, syringes with smaller apertures should be used as injection tools as much as possible during the injection process. First, it can reduce the difficulty of needle insertion and improve the feasibility of operation; second, small-aperture syringes can reduce the probability of leakage; third, small-aperture syringes can reduce mechanical damage to the joints caused by human factors, thereby more realistically reflecting the incidence of AGA caused by MSU crystal deposition.
[0105] 4. Selection of different injection sites: The MSU crystal injection method in the present invention refers to existing literature and is improved. The existing methods include the methods mentioned in the embodiments, such as vertical insertion of the ankle joint and forward insertion of the ankle joint. The vertical insertion of the ankle joint is simple to operate and the injection is smooth, but the injection volume is small in the vertical insertion. After experimental attempts, it was found that the maximum injection volume does not exceed 50 μL, and the modeling effect is somewhat different from the method described in the present invention. While the use of the joint forward insertion needle can better replicate the actual incidence of AGA, the modeling effect is good, and the onset is urgent, the anterior structure of the ankle joint is relatively complex, the difficulty of insertion is relatively large, and the operator's operation requirements are high. In addition, the anterior structure of the ankle joint is complex, and the blood vessels are relatively rich. The insertion process easily damages the blood vessels in the joint and causes bleeding.
[0106] 5. Selection of different injection doses: Since the onset of AGA is caused by the deposition of a large amount of MSU in the synovial membrane of the joint, injecting a larger dose of MSU can more realistically reflect the actual situation of AGA in the human body. The experimental results show that when the injection dose is 75μL, the modeling effect is the best.
[0107] 6. Selection of animals of different ages: During the modeling process, we found that 6-week-old and 8-week-old experimental animals had the best modeling effect and there was no significant difference. 6-week-old mice can reduce experimental costs when selecting animals. Therefore, we prefer to choose 6-week-old mice as experimental subjects.
[0108] 7. During the injection of the model, the needle should be inserted slowly and accurately, and the injection should be slow and steady. Since the injection dose has a great influence on the modeling effect, during the injection process, it should be noted that the MSU needle insertion depth is about 3mm. During the injection of MSU crystals, it should be observed whether there is leakage and bulge to ensure that all the MSU suspension is injected into the joint cavity. After the injection is completed, wait for 3 seconds to rotate the needle to remove the needle and observe whether there is leakage.
[0109] The present invention has made a series of improvements on the existing technology, reducing the difficulty of operation, shortening the experimental period and improving the stability of the model under the premise of accurately and efficiently replicating the AGA model. Therefore, the present invention provides an improved method for constructing an AGA mouse model, providing a set of standardized experimental schemes for accurately and efficiently replicating the animal model, and providing a set of simple and standard reference schemes for the establishment of AGA animal models in the future.
[0110] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A method for constructing an acute gouty arthritis mouse model, characterized in that: The following steps are involved: The sodium urate crystals are repeatedly beaten and squeezed and ground into powder, sodium chloride solution is added to the powder to resuspend it, and the resuspended liquid is subjected to ultrasonic treatment to harvest the sodium urate crystal suspension; the conditions of the ultrasonic treatment are: temperature of 45° C., ultrasonic power of 480 W, and ultrasonic time of 30 min; during the ultrasonic treatment, the resuspended liquid is shaken once every 5 min; The ankle joint of the mouse was placed at 90°, and a needle was inserted at an angle of 35° between the tendon of the right ankle joint of the mouse and the base of the lateral malleolus, and the sodium urate crystal suspension was injected; the injection volume of the sodium urate crystal suspension was 75 μL; The mice are C57BL / 6j mice, 6-8 weeks old; Before puncturing the ankle joint of the mouse, the mouse was anesthetized by intraperitoneal injection of 2.5% V / V tribromoethanol.
2. The construction method according to claim 1, characterized in that: The experimental consumables used for the injection are insulin syringes with a pore diameter of 0.25 mm.
3. Use of an acute gouty arthritis mouse model obtained by the construction method according to any one of claims 1 to 2 in screening therapeutic drugs for acute gouty arthritis.
